Back to News
Nov 21, 2025 12:00 PM

Novo Nordisk Will Soon Reveal Whether Its GLP-1 Drug Can Slow Alzheimer's

Upcoming data from Novo Nordisk A/S (NYSE:NVO) early next month could offer the clearest signal yet on whether GLP-1 medicines, widely used for diabetes and weight loss, can also slow the progression of Alzheimer's disease.

If Rybelsus shows close to a 30% reduction in cognitive decline, it would be viewed as a clear success, Reuters highlighted, citing an expert.

Even modest results could inform future trial designs or potential combination therapies with existing Alzheimer's drugs.

Novo will present findings on Dec. 3 at the Clinical Trials on Alzheimer's Disease meeting in San Diego.

The company is testing its oral diabetes drug Rybelsus, which contains semaglutide, the same active ingredient as ...